SecBot SecBot
SECBOTREPLAY Home › Report › ARQT

ARQT · Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream…

Arcutis Biotherapeutics, Inc. · PRESS-RELEASE filed Jun 29, 2026 at 19:06 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 29, 2026 at 19:06 ET

Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 years old, the seventh FDA approval for ZORYVE in four years. This addresses a significant treatment gap in pediatric psoriasis, where limited steroid-free options existed for young children. The approval is based on a Phase 2 MUSE study and long-term extension data showing safety and efficacy consistent with adult/adolescent trials.

  • FDA approved sNDA for ZORYVE cream 0.3% to treat plaque psoriasis in children down to age 2, including intertriginous areas
  • Seventh FDA approval for ZORYVE in four years; first once-daily steroid-free topical approved for ages 2+ with plaque psoriasis
  • Approval based on 4-week MUSE study (ARQ-151-216) in children ages 2-5 and 24-week open-label extension (ARQ-151-306)
  • ZORYVE cream 0.3% already approved for adults and children down to age 6; this expansion adds ages 2-5

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access